Dl-3-N-butylphthalide promotes angiogenesis in an optimized model of transient ischemic attack.

PMID: Front Pharmacol. 2021; 12: 751397. Epub 2021 Sep 29. PMID: 34658892 Abstract Title: Dl-3-N-Butylphthalide Promotes Angiogenesis in an Optimized Model of Transient Ischemic Attack in C57BL / 6 Mice. Abstract: Transient ischemic attack (TIA) has been widely regarded as a clinical entity. Even though magnetic resonance imaging (MRI) results of TIA patients are negative, … Read more

Dl-3-n-butylphthalide alleviates behavioral and cognitive symptoms via modulating mitochondrial dynamics in the A53T-α-synuclein mouse model of Parkinson’s disease.

PMID: Front Neurosci. 2021; 15: 647266. Epub 2021 May 28. PMID: 34121985 Abstract Title: Dl-3-n-Butylphthalide Alleviates Behavioral and Cognitive Symptoms Via Modulating Mitochondrial Dynamics in the A53T-α-Synuclein Mouse Model of Parkinson’s Disease. Abstract: BACKGROUND: Aggregation and neurotoxicity of the presynaptic proteinα-synuclein and the progressive loss of nigral dopaminergic neurons are believed to be the key … Read more

Butylphthalide could be a therapeutic potential against doxorubicin-induced neurotoxicity.

PMID: Oxid Med Cell Longev. 2018; 2018: 9125601. Epub 2018 Aug 16. PMID: 30186550 Abstract Title: Neuroprotective Effects of dl-3-n-Butylphthalide against Doxorubicin-Induced Neuroinflammation, Oxidative Stress, Endoplasmic Reticulum Stress, and Behavioral Changes. Abstract: Doxorubicin (DOX) is a broad-spectrum antitumor drug while its use is limited due to its neurobiological side effects associated with depression. We investigated … Read more